• BMS-345541: Redefining NF-κB Modulation in Translational Res

  2026-05-22

  Explore how BMS-345541 (free base) enables precise IKK-1/IKK-2 inhibition, bridging mechanistic insights with translational strategy for inflammation, cancer, and vascular biology.

• Palomid 529 (P529): Precision Inhibition of PI3K/Akt/mTOR in

  2026-05-22

  Palomid 529 (P529) enables researchers to dissect and target the PI3K/Akt/mTOR axis with unmatched specificity, making it crucial for investigating metastasis and chemoresistance in esophageal squamous cell carcinoma (ESCC). This article translates cutting-edge mechanistic insights into practical workflow guidance, with protocol details, troubleshooting, and strategic interlinks to empower translational oncology and beyond.

• (S)-(+)-Dimethindene maleate: Technical Guide for M2 Antagon

  2026-05-21

  (S)-(+)-Dimethindene maleate is a selective M2 muscarinic and H1 histamine receptor antagonist designed to support research into autonomic regulation, cardiovascular, and respiratory system function. It provides a defined tool for receptor selectivity studies but should not be used for diagnostic or clinical purposes. Researchers benefit from its solubility, purity, and workflow reliability, while adhering to well-documented storage and handling protocols.

• Dual-Action Airway Stent Suppresses Tracheal Restenosis in V

  2026-05-21

  Zhao et al. engineered a novel airway stent combining anti-inflammatory and anti-angiogenic agents to address tracheal in-stent restenosis (TISR), a persistent complication in airway interventions. Their integrated approach demonstrated effective suppression of fibrosis, angiogenesis, and infection in a rabbit model, with transcriptomic evidence supporting durable modulation of pro-inflammatory and pro-fibrotic pathways.

• Pulchinenoside B4 Mitigates Colitis via CD1d/NLRP3 in Macrop

  2026-05-20

  This study demonstrates that Pulchinenoside B4 (PB4) alleviates DSS-induced colitis in mice by targeting CD1d and inhibiting NLRP3 inflammasome activation specifically in macrophages. The findings highlight a targeted anti-inflammatory mechanism, paving the way for novel therapeutic strategies for ulcerative colitis.

• (S)-(+)-Dimethindene maleate for M2 Muscarinic Antagonism

  2026-05-20

  (S)-(+)-Dimethindene maleate is a highly selective M2 muscarinic receptor antagonist with additional H1 histamine receptor blocking activity, making it suitable for research into autonomic regulation, cardiovascular, and respiratory physiology. It should not be used in diagnostic or medical applications, and its use is limited to experimental settings that require precise receptor selectivity profiling.

• Thymosin-β4 Promotes Angiogenesis in CLI via Notch/NF-κB Mod

  2026-05-19

  This study uncovers how thymosin-β4 (Tβ4) induces angiogenesis in critical limb ischemia (CLI) by regulating the Notch and NF-κB pathways. Through genetic and pharmacological interventions, it elucidates a mechanistic framework for therapeutic vascular regeneration in ischemic disease models.

• Tin Mesoporphyrin IX (chloride): Unveiling Its Role in Redox

  2026-05-19

  Explore how Tin Mesoporphyrin IX (chloride) enables precise dissection of heme oxygenase activity and redox signaling in metabolic disease research. This article offers new insights into its application in modulating cellular ROS and interpreting assay outcomes, building on recent mechanistic breakthroughs.

• Antimycin A4: Streptomyces-Derived ATP-Citrate Lyase Inhibit

  2026-05-18

  The reference study identifies and characterizes Antimycin A4 among a suite of antimycins from Streptomyces sp., demonstrating potent inhibition of ATP-citrate lyase—a key enzyme in fatty acid and cholesterol biosynthesis. This dual-function antibiotic, also known for mitochondrial respiratory chain inhibition, provides researchers with a precise tool to dissect eukaryotic energy and lipid metabolism.

• Veratridine as a Voltage-Gated Sodium Channel Opener in Card

  2026-05-18

  Veratridine, a potent voltage-gated sodium channel opener, enables advanced sodium channel dynamics research and chamber-specific cardiomyocyte modeling. Learn how to harness its unique properties for reproducible excitotoxicity assays, screening for sodium channel blockers, and optimizing cardiac differentiation protocols.

• Patient-Derived Gastric Cancer Assembloids: Modeling Drug Re

  2026-05-17

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, advancing the physiological relevance of preclinical testing. The model reveals critical roles for stromal components in modulating drug responses and resistance, offering a robust platform for personalized therapy discovery.

• Hesperadin: Redefining Aurora B Inhibition in Translational

  2026-05-16

  This thought-leadership article dissects the mechanistic and strategic value of Hesperadin, a potent Aurora B kinase inhibitor, for translational researchers. Integrating recent advances in spindle assembly checkpoint biology with practical assay design and evidence-based recommendations, we position Hesperadin as a precision tool for interrogating mitotic progression, with a focus on cancer research applications. By bridging mechanistic insights from seminal checkpoint studies and comparative product intelligence, this article challenges translational teams to rethink their approach to cell cycle regulation and checkpoint disruption.

• Crizotinib Hydrochloride: Precision Tools for Tumor-Stroma A

  2026-05-15

  Explore how Crizotinib hydrochloride, a leading ALK kinase inhibitor, enables nuanced dissection of tumor-stroma interactions in advanced assembloid models. This article reveals new assay design strategies and practical insights for cancer biology research.

• pH-Responsive Hairpin ASO Prodrugs Enable Controlled MYCN Si

  2026-05-15

  This study presents a rationally designed, pH-responsive antisense oligonucleotide (ASO) prodrug system using i-motif hairpin structures for targeted gene silencing in MYCN-amplified tumor cells. By systematically tuning structural features, the authors achieved enhanced stability, controlled intracellular release, and potent in vitro antitumor effects, providing a blueprint for future stimulus-responsive nucleic acid therapeutics.

• SCH772984 HCl: Precision ERK1/2 Inhibitor for MAPK Studies

  2026-05-14

  SCH772984 HCl stands out as a potent, selective ERK1/2 inhibitor, enabling researchers to dissect MAPK pathway dependencies and overcome drug resistance in BRAF- and RAS-mutant models. Robust nanomolar potency, reproducible in vivo efficacy, and new applications in telomerase regulation make it a critical tool for cancer and stem cell research.

14664 records 3/978 page Previous Next 12345 下5页 Last page